306 related articles for article (PubMed ID: 22762411)
1. Feasibility of minimally invasive radical prostatectomy in prostate cancer patients with high prostate-specific antigen: feasibility and 1-year outcomes.
Do M; Ragavan N; Dietel A; Liatsikos E; Anderson C; McNeill A; Stolzenburg JU
Int J Urol; 2012 Oct; 19(10):923-7. PubMed ID: 22762411
[TBL] [Abstract][Full Text] [Related]
2. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
3. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
4. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
Yamamoto S; Kawakami S; Yonese J; Fujii Y; Urakami S; Masuda H; Numao N; Ishikawa Y; Kohno A; Fukui I
Jpn J Clin Oncol; 2012 Jun; 42(6):541-7. PubMed ID: 22457326
[TBL] [Abstract][Full Text] [Related]
5. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
6. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
7. Patterns of care for radical prostatectomy in the United States from 2003 to 2005.
Hu JC; Hevelone ND; Ferreira MD; Lipsitz SR; Choueiri TK; Sanda MG; Earle CC
J Urol; 2008 Nov; 180(5):1969-74. PubMed ID: 18801512
[TBL] [Abstract][Full Text] [Related]
8. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
9. Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach.
Salomon L; Levrel O; Anastasiadis AG; Saint F; de La Taille A; Cicco A; Vordos D; Hoznek A; Chopin D; Abbou CC
Prostate Cancer Prostatic Dis; 2002; 5(4):285-90. PubMed ID: 12627213
[TBL] [Abstract][Full Text] [Related]
10. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
[TBL] [Abstract][Full Text] [Related]
11. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
[TBL] [Abstract][Full Text] [Related]
12. Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score ≥ 8: a single-center experience.
Audenet F; Comperat E; Seringe E; Drouin SJ; Richard F; Cussenot O; Bitker MO; Rouprêt M
Urol Oncol; 2011; 29(6):602-7. PubMed ID: 19926312
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic extraperitoneal radical prostatectomy after previous transurethral resection of prostate: oncologic and functional outcomes of 100 cases.
Do M; Haefner T; Liatsikos E; Kallidonis P; Hicks J; Dietel A; Horn LC; Rabenalt R; Stolzenburg JU
Urology; 2010 Jun; 75(6):1348-52. PubMed ID: 19914701
[TBL] [Abstract][Full Text] [Related]
16. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
18. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
19. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
20. Surgical and oncological outcomes in patients with preoperative PSA >20 ng/ml undergoing robot-assisted radical prostatectomy.
Zugor V; Witt JH; Heidenreich A; Porres D; Labanaris AP
Anticancer Res; 2012 May; 32(5):2091-5. PubMed ID: 22593494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
